{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:21:37Z","timestamp":1759666897677},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ygyno.2014.05.030","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T19:29:32Z","timestamp":1401996572000},"page":"262-266","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer"],"prefix":"10.1016","volume":"134","clinical-trial-number":[{"clinical-trial-number":"nct00267696","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric L.","family":"Eisenhauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanna","family":"Zanagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbi","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.05.030_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0010","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0020","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0025","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0030","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0050","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic","volume":"13","author":"Ranieri","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0055","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0060","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0070","series-title":"J Clin Oncol 22","first-page":"5111","article-title":"Gemcitabine (GEM)+oxaliplatin (OX) in patients with stage III\/IV ovarian cancer following 3 cycles of carboplatin (CB)+paclitaxel (PAC): preliminary report of a phase II study","author":"Arca","year":"2004"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0075","series-title":"J Clin Oncol 22","first-page":"5104","article-title":"Biweekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatinum pretreated patients with relapsed ovarian cancer (roc): preliminary data of a phase II trial","author":"Germano","year":"2004"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0080","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ijrobp.2003.07.002","article-title":"Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma","volume":"58","author":"Wilkowski","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0085","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0090","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6690452","article-title":"Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines","volume":"80","author":"van Moorsel","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","article-title":"Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma","volume":"22","author":"Tewari","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group","volume":"103","author":"Brewer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ygyno.2006.09.006","article-title":"Biweekly gemcitabine and cisplatin in platinum-resistant\/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma","volume":"104","author":"Bozas","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0115","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-10-0832","article-title":"Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer","volume":"16","author":"Ledermann","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.05.030_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.09.013","article-title":"Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study","volume":"115","author":"Alvarez","year":"2009","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T16:22:21Z","timestamp":1538583741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814010257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0090825814010257"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.030","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}